This is a working overview of lactam bridge, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility class | Soluble in water and DMSO | Dissolves readily |
| Typical storage temperature | -20 °C or lower | Long-term, desiccated |
| Standard purity method | Reverse-phase HPLC | Area normalization |
| Freeze-thaw guidance | Limit to three cycles | Aliquot in advance |
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
However, general purpose computer programs that are used to derive equilibrium constant values from experimental data use association constants for both acids and bases. Because stability constants for a metal-ligand complex are always specified as association constants, ligand protonation must also be specified as an association reaction. The definitions show that the value of an acid dissociation constant is the reciprocal of the value of the corresponding association constant:
=== Fusimotor system === Muscle spindles relay information to the CNS via afferents, and they receive efferent signals from the spinal cord via gamma fusimotor neurons. This gamma innervation modulates the sensitivity of muscle spindle afferents to stretch. Gamma motoneurons are categorized according to the static and dynamic response properties of the muscle spindle afferents they affect. In recordings with semi-microelectrodes inserted into peripheral nerves in humans, muscle spindle afferent firing rates increased during muscle contraction. This suggested that gamma motoneuronal activity was linked to alpha motoneuronal activity (alpha-gamma co-activation). Only small movements were studied because electrodes otherwise dislodged. In studies of locomotion in decerebrate cats, gamma activity was shown to be correlated with cyclical variations in joint angle. In cats performing normal walking, beam-walking, landing from falls and resisting imposed movement, the mean firing rates of muscle spindle primary afferents and their sensitivity to variations in muscle length changed according to task. Sensitivity greatly increased in difficult tasks and in states of vigilance, presumably due to increases in dynamic gamma activity. The terms fusimotor "wind-up" and fusimotor "set" were coined to describe these behaviors.
In general, adsorption increases with decreasing temperature and increasing pressure (until a maximum is reached, typically 20–30 bar, after which the adsorption capacity decreases). However, MOFs to be used for hydrogen storage in automotive fuel cells need to operate efficiently at ambient temperature and pressures between 1 and 100 bar, as these are the values that are deemed safe for automotive applications.
Despite the signing of the Treaty of Peace and Friendship, Colon Freemasonry was still fundamentally divided between Eastern and Western Cuba and their cultural epicentres of Havana and Santiago de Cuba. José Fernández Pellón y Castellanos, leader of the Havana movement of Colon Freemasonry, entered into negotiations to relocate the Grand Lodge of Colon to Havana. He represented the interests of 27 Lodges in Western Cuba, all desiring that the Grand Lodge make the move. Soon after, the Grand Lodge of Colon did move to Havana, but the Supreme Council remained in Santiago de Cuba. On July 20, 1877, the Grand Lodge of Colon was officially reestablished in Havana, under Grand Master was Antonio Govín y Torres. The Masonic Lodges in their umbrella allowed for peaceful dialogues between Spanish reformists and Cuban pro-independence advocates. Several of the Colon Blue Lodges in Eastern Cuba did not agree with the decision. In 1877, some former members of the Grand Lodge of Colon at Santiago de Cuba established a second Grand Lodge of Colon at Havana. From 1877 to 1879, there were three Grand Lodges in Cuba operating simultaneously, all making the claim to be the "Regular" Grand Lodge.
Sources: en.wikipedia.org
Brain natriuretic peptide (BNP), also known as B-type natriuretic peptide, is a peptide hormone secreted by cardiomyocytes in the heart ventricles in response to stretching caused by increased ventricular blood volume. BNP is one of the three natriuretic peptides, in addition to atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). BNP was first discovered in porcine brain tissue in 1988, which led to its initial naming as "brain natriuretic peptide", although subsequent research revealed that BNP is primarily produced and secreted by the ventricular myocardium (heart muscle) in response to increased ventricular blood volume and stretching. To reflect its true source, BNP is now often referred to as "B-type natriuretic peptide" while retaining the same acronym. The 32-amino acid polypeptide BNP-32 is secreted attached to a 76–amino acid N-terminal fragment in the prohormone called NT-proBNP (BNPT), which is biologically inactive. Once released, BNP binds to and activates the atrial natriuretic factor receptor NPRA, and to a lesser extent NPRB, in a fashion similar to atrial natriuretic peptide (ANP) but with 10-fold lower affinity. The biological half-life of BNP, however, is twice as long as that of ANP, and that of NT-proBNP is even longer, making these peptides better targets than ANP for diagnostic blood testing. The physiologic actions of BNP are similar to those of ANP and include decrease in systemic vascular resistance and central venous pressure as well as an increase in natriuresis.
Food and Drug Administration (FDA) has issued a black box warning for suicidal behavior/ideation. Similar warnings have been issued in Australia. Unlike stimulant medications, atomoxetine does not have misuse liability or the potential to cause withdrawal effects upon abrupt discontinuation. Atomoxetine has been found to directly inhibit hERG potassium currents with an IC50Tooltip half-maximal inhibitory concentration of 6,300 nM, which has the potential to cause arrhythmia. No substantial QTc interval changes were observed in a clinical study of atomoxetine in CYP2D6 poor metabolizers. However, small changes could not be ruled out, and there was a slight but significant increase in QTc interval with higher atomoxetine concentrations. QT prolongation has been reported with atomoxetine at therapeutic doses and in overdose; it is suggested that atomoxetine not be used with other medications that may prolong the QT interval, concomitantly with CYP2D6 inhibitors, and caution to be used in poor metabolizers. Unlike α2-adrenergic receptor agonists such as guanfacine and clonidine, atomoxetine's use can be abruptly stopped without significant withdrawal symptoms being observed.
=== Spinal puncture === Following spinal anesthesia or puncture, people who are being treated with anti-thrombotic agents are at higher risk for developing a hematoma, which causes long-term or permanent paralysis. The risk of this may be increased by using epidural or intrathecal catheters after a surgical operation or from the concurrent use of medicinal agents that affect hemostasis.
=== 1990s: Early development of AI and open-source software === The concept of AI dates back to the mid-20th century, when computer scientists like Alan Turing and John McCarthy laid the groundwork for modern AI theories and algorithms. An early form of AI, the natural language processing "doctor" ELIZA, was re-implemented and shared in 1977 by Jeff Shrager as a BASIC program, and soon translated to many other languages. Early AI research focused on developing symbolic reasoning systems and rule-based expert systems. During this period, the idea of open-source software was beginning to take shape, with pioneers like Richard Stallman advocating for free software as a means to promote collaboration and innovation in programming. The Free Software Foundation, founded in 1985 by Stallman, was one of the first major organizations to promote the idea of software that could be freely used, modified, and distributed. The ideas from this movement eventually influenced the development of open-source AI, as more developers began to see the potential benefits of open collaboration in software creation, including AI models and algorithms. In the 1990s, open-source software began to gain more traction, the rise of machine learning and statistical methods also led to the development of more practical AI tools. In 1993, the CMU Artificial Intelligence Repository was initiated, with a variety of openly shared software.
=== Enzymatic debridement === Chemical enzymes are fast-acting products that slough off necrotic tissue. These enzymes are derived from micro-organisms including Clostridium histolyticum; or from plants, examples include collagenase, varidase, papain, and bromelain. Some of these enzymatic debriders are selective, while some are not. This method works well on wounds (especially burns) with a large amount of necrotic debris or with eschar formation. However, the results are mixed and the effectiveness is variable. Therefore, this type of debridement is used sparingly and is not considered a standard of care for burn treatments.
Sources: en.wikipedia.org
== WHO prequalified products == The World Health Organization Immunization Devices Prequalification (IMD-PQS) programme maintains a list of immunization cold chain equipment that it has prequalified for procurement and use by national immunization programmes of the WHOs Expanded Programme on Immunization (EPI), including refrigerators. IMD-PQS prequalifies products based on rigorous performance specifications that it develops in collaboration with national immunization programmes and in consultation with product manufacturers, to ensure that products address the specific needs of immunization programmes’ operating environments.
Within maritime environments one of the largest pest threats to waterlogged wood includes shipworms (Teredinidae). Shipworms bore into wood that is immersed in seawater. Within a museum exhibit or storage environment and post treatment of waterlogged wood objects, there are a number of wood-boring pests that feast on wood. Two of which include the wood-boring/powderpost beetle and termites. Wood-boring beetles can include several different types within the board category. Each type of beetle could target a different type of wood. Evidence of pest deterioration includes powder-like frass near entry and exit holes within the wood. Termites also feast on and live below the surface of the wood so they can be more difficult to detect. Termites discharge six-sided fecal pellets and, if found on a wooden object, could be used to determine the type of pest damage
Family studies show that T1D has a relatively high heritability, with siblings of affected individuals having about a 6–10% risk of developing the disease, compared to a 0.3% risk in the general population. The risk of T1D is also influenced by the presence of affected first-degree relatives. For instance, children of fathers with T1D have a higher risk of developing the disease compared to children of mothers with T1D. Monozygotic (identical) twins have a concordance rate of about 30–50%, highlighting the importance of both genetic and environmental factors in disease onset. Recent research has also focused on the role of epigenetics and gene-environment interactions in T1D development. Environmental factors such as viral infections, early childhood diet, and gut microbiome composition are thought to trigger the autoimmune process in genetically susceptible individuals. Epigenetic modifications, such as DNA methylation and histone modifications, may influence gene expression in response to these environmental triggers, further modulating the risk of developing T1D. While much progress has been made in understanding the genetic basis of T1D, ongoing research aims to unravel the complex interplay between genetic susceptibility, immune regulation, and environmental influences that contribute to disease pathogenesis.
Eurycoma longifolia (commonly called tongkat ali, Malaysian ginseng or long jack) is a flowering plant in the family Simaroubaceae. It is native to Indochina (Cambodia, Laos, Malaysia, Myanmar, Thailand and Vietnam) and Indonesia (the islands of Borneo and Sumatra), but has also been found in the Philippines. The plant is a medium-sized slender shrub that can reach 10 m (33 ft) in height, and is often unbranched. The root has been used in traditional medicine in Southeast Asia over centuries. It is also a widely used dietary supplement by bodybuilders, who believe that it increases testosterone levels and athletic performance, although there is no clinical evidence for its effectiveness on health or any disease. Rare cases of liver injury have occurred from its use, mostly in bodybuilders.
Sources: en.wikipedia.org
Cold storage at minus twenty degrees Celsius or below is typical, with desiccant and protection from light. The solid form is far more stable than any solution.
Repeated freeze-thaw cycles, alkaline pH, and exposure to light or oxygen are the main drivers. Moisture uptake by the solid also matters.
Mass spectrometry provides the strongest single identity check by matching the observed molecular ion to the expected value. Chromatographic retention time alone is not sufficient.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.